Journal: Biochemical pharmacology
Article Title: The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis.
doi: 10.1016/j.bcp.2023.115921
Figure Lengend Snippet: Fig. 6. IS4 binding to CXCR4 is similar to the binding of the CXCL12 mimetic compounds AMD3100 and peptide 10 to CXCR4. Immunofluorescence micro scopy of MCF-7 breast cancer cells shows positive expression of CXCR4 (green), visualized using either 12G5 mouse anti-CXCR4 monoclonal antibody (mAb) (binds to the extracellular loops 1 and 2 of CXCR4) or 4G10 mouse anti-CXCR4 mAb (binds to the N-terminus of CXCR4), plus secondary anti-mouse Alexa Fluor® 488 with nuclei indicated by DAPI staining (blue). No antagonist was used for positive controls. Negative control visualized using secondary anti- mouse Alexa Fluor® 488 and DAPI staining only. The CXCL12 mimetic com pounds AMD3100 and peptide 10 bind to similar residues on CXCR4 as compared to 12G5 therefore, in the presence of these compounds, fluorescence is lost. Fluorescence is restored with use of the 4G10 anti-CXCR4 mAb in place of 12G5. Data shows representative images from N = 4 acquired with Leica imaging suite using a 63x objective.
Article Snippet: Cells were washed twice in ice-cold 1X PBS then incubated with 1:200 primary mouse 12G5 anti-CXCR4 (sc-12764, Santa Cruz Biotechnology, Heidelberg, Germany) for 1 h at 4 ◦C.For negative control, no primary antibody was added.
Techniques: Binding Assay, Immunofluorescence, Expressing, Staining, Negative Control, Fluorescence, Imaging